← Leaderboards
Louis Staudt
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaLymphomaOncogenicLaboratoriesPathway InteractionsGeneticNf-Kappa BLarge Cell Diffuse Non-Hodgkin&AposMutationSignal TransductionBaseGenesMolecularB-LymphocytesCell LineRecurrenceMalignant Lymphoid NeoplasmCellsRegulatory PathwayMalignant NeoplasmsGenomicsGene Expression ProfilingMolecular TargetAffect
Grant awards (76)
Functional genomic screens for molecular targets in cancer$1,577,900
ZIA · FY2025 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$1,577,900
ZIA · FY2025 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,577,900
ZIA · FY2025 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,577,900
ZIA · FY2025 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,454,350
ZIA · FY2024 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$1,454,350
ZIA · FY2024 · CA · contact PI
Functional genomic screens for molecular targets in cancer$1,454,350
ZIA · FY2024 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,454,350
ZIA · FY2024 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,445,697
ZIA · FY2023 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,445,697
ZIA · FY2023 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$1,445,697
ZIA · FY2023 · CA · contact PI
Functional genomic screens for molecular targets in cancer$1,445,697
ZIA · FY2023 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,450,380
ZIA · FY2022 · CA · contact PI
Functional genomic screens for molecular targets in cancer$1,450,380
ZIA · FY2022 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$1,450,380
ZIA · FY2022 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,450,380
ZIA · FY2022 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,418,557
ZIA · FY2021 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,418,557
ZIA · FY2021 · CA · contact PI
Functional genomic screens for molecular targets in cancer$1,418,557
ZIA · FY2021 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$1,418,557
ZIA · FY2021 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,111,940
ZIA · FY2020 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,111,940
ZIA · FY2020 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,111,940
ZIA · FY2020 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$889,551
ZIA · FY2020 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$222,389
ZIA · FY2020 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,418,261
ZIA · FY2019 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,418,261
ZIA · FY2019 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,418,261
ZIA · FY2019 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$1,134,609
ZIA · FY2019 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$283,652
ZIA · FY2019 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,346,811
ZIA · FY2018 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,346,811
ZIA · FY2018 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,346,811
ZIA · FY2018 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$1,077,450
ZIA · FY2018 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$269,362
ZIA · FY2018 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,226,826
ZIA · FY2017 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,226,826
ZIA · FY2017 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,226,826
ZIA · FY2017 · CA · contact PI
Clinical development of mechanism-based lymphoma therapies$981,462
ZIA · FY2017 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$245,365
ZIA · FY2017 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$936,810
ZIA · FY2016 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$936,810
ZIA · FY2016 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$936,810
ZIA · FY2016 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$936,810
ZIA · FY2016 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,283,581
ZIA · FY2015 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$1,283,581
ZIA · FY2015 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,283,581
ZIA · FY2015 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,283,581
ZIA · FY2015 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$1,263,868
ZIA · FY2014 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,263,868
ZIA · FY2014 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,263,868
ZIA · FY2014 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,263,868
ZIA · FY2014 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,407,103
ZIA · FY2013 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,407,103
ZIA · FY2013 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,407,103
ZIA · FY2013 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$1,407,103
ZIA · FY2013 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$1,013,664
ZIA · FY2012 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$1,013,664
ZIA · FY2012 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$1,013,664
ZIA · FY2012 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$1,013,664
ZIA · FY2012 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$971,205
ZIA · FY2011 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$971,205
ZIA · FY2011 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$971,205
ZIA · FY2011 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$971,205
ZIA · FY2011 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$838,914
ZIA · FY2010 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$838,914
ZIA · FY2010 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$838,914
ZIA · FY2010 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$838,914
ZIA · FY2010 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$800,463
ZIA · FY2009 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$800,463
ZIA · FY2009 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$800,463
ZIA · FY2009 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$800,463
ZIA · FY2009 · CA · contact PI
Oncogenic mechanisms and molecular targets in myeloma$770,465
Z01 · FY2008 · CA · contact PI
Oncogenic mechanisms and molecular targets in lymphoma$770,465
Z01 · FY2008 · CA · contact PI
RNA interference-based screens for molecular targets in cancer$770,465
Z01 · FY2008 · CA · contact PI
Molecular diagnosis and outcome prediction in lymphoma$770,465
Z01 · FY2008 · CA · contact PI